Newsroom

Cardiovascular disease (CVD) and cancer are the two leading causes of death in the U.S. According to researchers from The University of Texas MD Anderson Cancer Center, patients diagnosed with late-stage or metastatic breast cancer have a statistically significant increased risk of pre-diagnosis CVD compared to those with early-stage cancer at diagnosis.

The study, published today in JAMA Network Open, found those with advanced...

The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. today announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer (CRC) and minimal residual disease (MRD) as well as those with MRD in other solid tumors.

Under the agreements, AmMax and MD Anderson will...